Immunomedics Inc

IMMU 
(NASDAQ) 
 
$ 14.22 <%= Resources.Global.txtDown %>
Updated 14/07/2019
Change % -3.07% Stock price decreasing
Change -0.45 Stock price decreasing
Volume 1,101,327
High $ 14.76
Low $ 14.11
Open $ 14.67
ISIN
Prev close $ 14.67
# of shares 191.54M
Market cap 2,723.66M USD
Intraday

Market closed
Immunomedics Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  14.22 1.6% Stock price increasing 15.0% Stock price increasing -18.7% Stock price decreasing -20.2% Stock price decreasing -44.2% Stock price decreasing
Powered by TradingView

News about Immunomedics Inc

  • English
  • Regulatory news

Company profile

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2019 04:01:10
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB5 - 2019-07-16 05:01:10 - 2019-07-16 04:01:10 - 1000 - Website: OKAY